Baird lowered the firm’s price target on Agenus to $35 from $120 and keeps an Outperform rating on the shares. Teh target change refelcts its 1-for-20 reverse stock split. Additionally, the company provided an updated look at Phase 1 data for botensilimab (CTLA-4) and balstilimab (PD-1) in MSS CRC that continued to highlight meaningful survival.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
